Edward A. Stadtmauer, MD, Section Chief for Hematological Malignancies at the Abramson Cancer Center offers a comprehensive update on recent advances in the diagnosis, treatment and clinical research for the hematologic malignancies, including multiple myeloma, the acute and chronic myeloid and lymphocytic leukemias, Hodgkin and non-Hodgkin lymphoma and mantle cell lymphoma. Dr. Stadtmauer’s discussion includes an overview of clinical research, novel drug therapies-including ibrutinib-and a review of integrated mutational profiling and its value.
Related Links
- Clinical Briefing: Restoration of Immunity in Lymphopenic Patients with Cancer via Immunotherapy with Vaccination and Adoptive T cell Transfer
- Case Study: A 51-year-old man with a lytic lesion in the 7th rib, a compression fracture at T12, monoclonal IgA antibody in his blood, and a bone marrow biopsy showing 46% plasma cells, all consistent with the diagnosis of multiple myeloma.
- Dr. Stadtmauer’s Profile
Published
April 22, 2015
Created by
BROADCASTMED